Algeria vs Australia: HIV/AIDS deaths averted by antiretroviral therapy
Algeria
1,007 deaths
in 2024
Australia
989.62 deaths
in 2022
Algeria rank
73rd
Australia rank
74th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Algeria
- Australia
How they compare
Algeria currently reports 1,007 deaths against 989.62 deaths in Australia, a difference of 17.38 deaths.
Across all 33 years both countries report, Australia has been ahead every year.
Algeria ranks 73rd and Australia ranks 74th of 157 countries.
Australia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Algeria | Australia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4.15 deaths | 260.07 deaths | 255.92 deaths | Australia |
| 2000s | 78.66 deaths | 740.59 deaths | 661.93 deaths | Australia |
| 2010s | 458.68 deaths | 840.56 deaths | 381.88 deaths | Australia |
| 2020s | 848.41 deaths | 982.57 deaths | 134.16 deaths | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Algeria or Australia?
- Algeria, at 1,007 deaths against 989.62 deaths in Australia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Algeria and Australia?
- 17.38 deaths, with Algeria ahead.
- How many years of comparable data are there for Algeria and Australia?
- 33 years are reported by both, from 1990 to 2022.
- How do Algeria and Australia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Algeria ranks 73rd and Australia ranks 74th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.